PharmaLegacy will focus on the proof of concept development of OVM’s two lead vaccines, OVM-100 and OVM-200, focusing on unmet clinical need. OVM-100 is an HPV vaccine targeted at cervical cancer, and OVM-200 represents a new type of vaccine utilising survivin to target solid tumours. Both vaccines will be tested as single agents and in combination with other immune-oncology (IO) agents.
Spun out from the University of Oxford, OVM is commercialising the research led by Dr Shisong Jiang and developed in Oxford University’s Department of Oncology. The technology uses the novel, proprietary platform of recombinant overlapping peptides to design and develop therapeutic cancer vaccines and diagnostics with the potential for increased efficacy, lower costs, simpler regulatory pathways and synergy when used in combination with other IO agents.
OVM secured Series A investment from Cancer ROP, a leading South Korean healthcare institution, listed in KOSDAQ, and from existing shareholders in China. The financing round represents the first time that a UK cancer vaccines company has been financed by both South Korean and Chinese investors.
William Finch, CEO and Director at OVM, said:
“We are very pleased to have such an experienced company as PharmaLegacy involved in this important phase in the development of our cancer vaccines. This work will be pivotal to OVM’s cancer vaccines being progressed to important clinical milestones both to benefit patients and to return significant shareholder value. We already have strong partnerships in China and in the Republic of Korea and this appointment is key to our future success for the development of our immunotherapy vaccines”
Jeff Duan, CEO and President of PharmaLegacy, added:
“We are delighted to have been appointed to complete the proof of concept work on Oxford Vacmedix’s two lead immunotherapy cancer vaccines and look forward to a productive and beneficial partnership with Oxford Vacmedix. We are confident that we can support the continued growth and development of the company.”
For more information or to arrange an interview, please contact:
William Finch, CEO, Oxford Vacmedix
T: +44 (0)1865 742074 | M: +44(0)7769 903711 | E: email@example.com
About Oxford Vacmedix
Oxford Vacmedix UK Ltd, based on the Oxford Science Park, UK, is a bio-pharma company that utilizes the novel proprietary platform technology of recombinant overlapping peptides (ROPs) invented by Dr Shisong Jiang. ROPs have been validated as a technology to stimulate broad and strong T cell immunity therefore forming a good platform for cancer therapeutic vaccines and diagnostics. The company is a spin-out of the University of Oxford and has extensive contacts and collaborations in China through Changzhou Bioscience that is using the ROP platform in both diagnostics and adoptive cell therapy.
For more information, please visit: www.oxfordvacmedix.com/contact
About PharmaLegacy, Shanghai
PharmaLegacy Laboratories (PL), is a leading speciality pharmacology Contract Research Organization located in Shanghai, Zhangjiang High-Tech Park, China. PL provides preclinical pharmacology services in Immuno-Oncology (Oncology), Inflammation/Auto-Immune diseases, Bone/Orthopaedics and Liver/Metabolic diseases, and in biologics testing. PL’s core competency stems from its pioneering work in running clinically predictive animal disease models to test drug candidates and medical devices for pharmacological effects and biocompatible repairs. In addition to efficacy studies, PL provides services in PK/PD, ADA, molecular pharmacology and non-GLP toxicology. Overall PL provides all preclinical pharmacological services from early proof of concept of therapeutics to fulfilment of regulatory requirements.
For more information, please visit: http://www.pharmalegacy.com